| Dr Ann Marie S Rockamann, MD | |
|
3023 N Ballas Rd Ste 600d, Saint Louis, MO 63131-2332 | |
| (314) 996-4880 | |
| Not Available |
| Full Name | Dr Ann Marie S Rockamann |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 33 Years |
| Location | 3023 N Ballas Rd Ste 600d, Saint Louis, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013943406 | NPI | - | NPPES |
| 110176 | Other | MO | BLUE CROSS BLUE SHIELD |
| 5629009 | Other | MO | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 103120 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Missouri Baptist Medical Center | Town and country, MO | Hospital |
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Mercy Hospital St Louis | Saint louis, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physician Groups Lc | 3072421254 | 409 |
News Archive
HIV epidemics are emerging among people who inject drugs in several countries in the Middle East and North Africa. Though HIV infection levels were historically very low in the Middle East and North Africa, substantial levels of HIV transmission and emerging HIV epidemics have been documented among people who inject drugs in at least one-third of the countries of this region, according to findings published today in PLOS Medicine.
New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug's overall tolerability without affecting its efficacy, say Japanese researchers.
Scientists have identified a genomic "signature" in circulating blood that reveals exposure to common upper respiratory viruses, like the cold or flu, even before symptoms appear.
Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery.
› Verified 8 days ago
| Entity Name | Physician Groups Lc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285664268 PECOS PAC ID: 3072421254 Enrollment ID: O20040220001157 |
News Archive
HIV epidemics are emerging among people who inject drugs in several countries in the Middle East and North Africa. Though HIV infection levels were historically very low in the Middle East and North Africa, substantial levels of HIV transmission and emerging HIV epidemics have been documented among people who inject drugs in at least one-third of the countries of this region, according to findings published today in PLOS Medicine.
New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug's overall tolerability without affecting its efficacy, say Japanese researchers.
Scientists have identified a genomic "signature" in circulating blood that reveals exposure to common upper respiratory viruses, like the cold or flu, even before symptoms appear.
Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ann Marie S Rockamann, MD 3023 N Ballas Rd Ste 600d, Saint Louis, MO 63131-2332 Ph: (314) 996-4880 | Dr Ann Marie S Rockamann, MD 3023 N Ballas Rd Ste 600d, Saint Louis, MO 63131-2332 Ph: (314) 996-4880 |
News Archive
HIV epidemics are emerging among people who inject drugs in several countries in the Middle East and North Africa. Though HIV infection levels were historically very low in the Middle East and North Africa, substantial levels of HIV transmission and emerging HIV epidemics have been documented among people who inject drugs in at least one-third of the countries of this region, according to findings published today in PLOS Medicine.
New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.
Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug's overall tolerability without affecting its efficacy, say Japanese researchers.
Scientists have identified a genomic "signature" in circulating blood that reveals exposure to common upper respiratory viruses, like the cold or flu, even before symptoms appear.
Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery.
› Verified 8 days ago
Dr. Patricia Tereese Jimenez, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4444 Forest Park Ave, Div Ob Reproductive Endocrinology, Ste 3100, Saint Louis, MO 63108 Phone: 314-286-2400 Fax: 314-286-2455 | |
Anna Rabinov, ANNA RABINOV Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-747-3000 | |
Shannon Michelle Grabosch, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1031 Bellevue Ave Ste 400, Saint Louis, MO 63117 Phone: 314-781-4772 Fax: 314-645-8771 | |
Dr. Kathryn Botney, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 621 S New Ballas Rd, Suite 4005, Saint Louis, MO 63141 Phone: 314-567-5016 Fax: 314-567-1846 | |
Dr. Haifaa T. Younis, M.D Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2315 Dougherty Ferry Rd, Suite 109b, Saint Louis, MO 63122 Phone: 314-965-5553 Fax: 314-590-5972 | |
Dr. Renee M Stein, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 10777 Sunset Office Dr, Suite 200, Saint Louis, MO 63127 Phone: 314-842-4802 Fax: 314-849-8721 |